A Randomized, Prospective Trial of 2-6 Weeks Pre-Operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-Study)

Trial Profile

A Randomized, Prospective Trial of 2-6 Weeks Pre-Operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - Response in Molecular Profile (AFTER-Study)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2016

At a glance

  • Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Tamoxifen
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms AFTER
  • Most Recent Events

    • 10 May 2016 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
    • 10 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
    • 12 Dec 2015 Interim results (n=28) presented at the 38th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top